Table 1.

Reported cases of gross hematuria following COVID-19 vaccination in IgAN patients

IgAN	Age (yr)/sex	Vaccine	Dose	Latent period (day)	Systemic sign/symptom	Initial sign	Duration of gross hematuria	Residual sign	Reporta
Known	22/male	MO	1st	2	Arthralgia	H, P	ND	No	Perrin et al., 2021
			2nd	2
Known	41/female	PB	1st	2	Leukocytosis	C	ND	No	Perrin et al., 2021
Known	13/male	PB	2nd	<1	Vomiting	H, C	2 days	No	Hanna et al., 2021
Known	38/female	MO	2nd	1	Fever	H, P	3 days	P	Negrea et al., 2021
Known	38/female	MO	2nd	1	Fever	H	3 days	No	Negrea et al., 2021
Known	52/female	PB	2nd	1	Fever	H, P	5 days	P	Rahim et al., 2021
Known	ND/male	PB	2nd	1	Fever	H, P	3 days	No	Plasse et al., 2021
Known	22/female	MO	2nd	<2	ND	H, P	<1 month	P	Park et al., 2021
Known	39/female	MO	2nd	<2	ND	H, P	<1 month	No	Park et al., 2021
Known	27/female	PB	2nd	2	Pancytopenia	H	ND	No	Perrin et al., 2021
Known	ND/male	PB	2nd	6	Myalgia	H, C, P	ND	C, P	Plasse et al., 2021
Known	78/female	MO	ND	7	Diarrhea	H	15 days	No	Obeid et al., 2021
Known	27/female	PB	2nd	2	Fever	H, P	4 days	No	Presenting case
De novo	39/male	MO	2nd	Immediately	Fever	H, C, P	weeks	H	Anderegg et al., 2021
De novo	17/male	PB	2nd	<1	Hypertension	H, C, P	5 days	C, P	Hanna et al., 2021
De novo	41/female	PB	2nd	1	Myalgia	H, C, P	ND	ND	Tan et al., 2021
De novo	50/male	MO	2nd	1	Rash	H, C, P	<1 month	C, P	Park et al., 2021
De novo	50/female	MO	2nd	2	Fever	H, C, P	5 days	ND	Kudose et al., 2021
De novo	19/male	MO	2nd	2	ND	H, C	2 days	ND	Kudose et al., 2021
De novo	30/male	MO	2nd	1	Fever	H, P	2 days	P	Abramson et al., 2021

C, increased creatinine; COVID-19, coronavirus disease-19; F, female; H, gross hematuria; IgAN, immunoglobulin A nephropathy; M, male; MO, Moderna; ND, no data; P, increased proteinuria; PB, Pfizer-BioNTech.

^aSee the Supplementary material (available online) for the references below.